# Eosvision

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/eosvision

- Industry: Medical Devices & Equipment
- Headquarters: Suzhou, China
- Total disclosed funding: $14M
- Latest round: Series A (Dec 6, 2024)
- Investors on record: 1

## About

Founded in 2020 and based in Suzhou, China, Eosvision operates as a medical instrument manufacturing company that focuses on the production and sales of ophthalmic implantable medical devices. The company's founding team has more than 15 years of R&D and management experience in the pharmaceutical field. The company has a R&D and production site of about 5,600 square meters, and has built three static ISO 7 clean production workshops. In December 2024, Eosvision raised approximately CNY 100 million in series A funding. In May 2025, Eosvision closed series A+ funding.

The company's main business is the research and development and production of passive implantable medical devices. The product pipeline includes artificial bionic cornea, implantable contact lenses, artificial corneal endothelial membrane, artificial dermis, etc. The company's research and development of polymer materials and synthetic self-assembled triple helical structure bionic collagen materials cross-linking copolymerization technology can achieve product biocompatibility improvement, protein adhesion reduction, and calcification deposition reduction.

The company generates revenue by providing ophthalmic implantable medical devices.

The company will use the series A funding to advance the research and development of innovative ophthalmic and regenerative medicine products in the pipeline, such as artificial bionic corneas, implantable contact lenses, artificial corneal endothelial sheets, and artificial dermis, as well as human clinical trials, international development, registration, and marketing expansion.

## Funding rounds

- Series A, Dec 6, 2024, $14M — Dalton Venture

## Investors

- Dalton Venture (https://capitalatlas.ai/funds/dalton-venture) — Series A